Generate Biomedicines, Inc.

As of June 30, 2026, Generate Biomedicines, Inc. carries a market capitalization of 2.16B, placing it among publicly traded companies globally. Its enterprise value stands at 1.77B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Generate Biomedicines, Inc.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Generate Biomedicines, Inc. has 128.27M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Generate Biomedicines, Inc. maintains a current ratio of 8.30, meaning it holds 8.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.73, indicating elevated leverage, while an interest coverage ratio of -441.23 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 20,237.18 in revenue per employee across its workforce of 312.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Generate Biomedicines, Inc. recorded 53,000.00 in income tax expense.

These figures are as of the close on October 22, 2026.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, Generate Biomedicines, Inc. holds 457.42M in cash and equivalents against 62.63M in total debt, resulting in a net debt position of -135.36M. Total book value stands at 456.05M, with working capital of 413.62M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. After subtracting -933,000.00 in capital expenditures, free cash flow totaled -58.88M - equivalent to -0.46 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -1,134.21 and net profit margin of -1,065.17 provide insight into operational efficiency.